- Latest available (Revised)
- Point in Time (01/05/2004)
- Original (As made)
Point in time view as at 01/05/2004.
There are currently no known outstanding effects for the The Medicines for Human Use (Clinical Trials) Regulations 2004,
PART 2
.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
1. In the Medicines (Standard Provisions for Licences and Certificates) Regulations 1971 F1—U.K.
(a)in regulation 2 (interpretation), in the definition of “clinical trial certificate of right”and “animal test certificate of right,”omit “ “clinical trial certificate of right” and”;
(b)in regulation 3 (standard provisions for licences and certificates), omit paragraph (2); and
(c)in Schedule 1, omit Part II (standard provisions for clinical trial certificates and clinical trial certificates of right).
Textual Amendments
F1S.I. 1971/972; regulation 3(3) and Part III of Schedule 1 are revoked insofar as they apply to animal test certificates by S.I. 2003/3309.
2. In the Medicines (Surgical Materials) Order 1971 F2, in article 3, for the words from “, the provisions contained in Parts I and II of the Act” to the end substitute—U.K.
“(a)the provisions contained in Parts I and II of the Act, sections 62, 64, 65 and 67 of Part III of the Act, and the provisions contained in Parts V, VI and VIII of the Act shall have effect in relation to the said articles or substances described in the Schedule to this Order, as those provisions have effect in relation to medicinal products; and
(b)the provisions of the Clinical Trials Regulations shall have effect in relation to the said articles or substances.”.
Textual Amendments
F2S.I. 1971/1267, as amended by S.I. 1994/3119.
3.—(1) In the Medicines (Exemption from Licences) (Special Cases and Miscellaneous Provisions) Order 1972 F3, article 4 shall be amended as follows.U.K.
(2) In paragraph (1)—
(a)for “sections 7, 31(2) and 32” substitute “ sections 7 and 32 ”;
(b)in subparagraph (a), omit “a clinical trial, or, as the case may be,”.
(3) In paragraph (2)—
(a)in subparagraph (i)—
(i)in paragraph (a), omit “a clinical trial, or, as the case may be,”,
(ii)in paragraph (b), omit “clinical trial or”;
(b)in subparagraph (iii)—
(i)omit “the clinical trial or, as the case may be,”,
(ii)omit the words from “the doctor or dentist” to “as the case may be,”;
(c)in subparagraph (iv)—
(i)omit the words from “that the doctor or dentist” to “as the case may be,”,
(ii)omit the words “the trial, or, as the case may be”.
(4) Omit paragraph (3).
Textual Amendments
4. In the Medicines (Dental Filling Substances) Order 1975 F4, in article 2, in paragraph (1), for the words from “the following provisions of the Act” to the end substitute—U.K.
“(a)the provisions contained in Parts I, II, III, V, VI and VIII of the Act shall have effect in relation to dental filling substances as those provisions have effect in relation to medicinal products; and
(b)the provisions of the Clinical Trials Regulations shall have effect in relation to those substances.”.
Textual Amendments
F4S.I. 1975/533, as amended by S.I. 1994/3119.
5. In the Medicines (Specified Articles and Substances) Order 1976 F5, in article 2, in paragraph (1), for the words from “the provisions of the Act” to the end substitute—U.K.
“(a)the provisions of the Act set out in Part I of the said Schedule 2 shall have effect in relation to such articles or substances as those provisions have effect in relation to medicinal products; and
(b)the provisions of the Clinical Trials Regulations shall have effect in relation to those articles or substances.”.
Textual Amendments
F5S.I. 1976/968, as amended by S.I. 1994/3119.
6.—(1) The Medicines (Labelling) Regulations 1976 F6 shall be amended as follows.U.K.
(2) In regulation 1 (citation and scope) F7, after “apply”, insert “ or a medicinal product which is an investigational medicinal product within the meaning of the Medicines for Human Use (Clinical Trials) Regulations 2003 ”.
(3) In regulation 2 (commencement), in paragraph (b), in sub-paragraph (i), omit “, clinical trial certificate”.
(4) Omit regulation 6 (clinical trials).
(5) In regulation 10 (surgical materials), omit the words from “, except that” to the end.
(6) In regulation 16 (provisions in licences, clinical trial certificates and animal test certificates)—
(a)in paragraph (1), for “a clinical trial certificate or animal test certificate ” substitute “ an animal test certificate ”;
(b)in paragraph (2), omit “, clinical trial certificate”.
(7) Omit Schedule 2 (particulars required in the labelling of containers and packages of medicinal products for clinical trials).
Textual Amendments
F6S.I. 1976/1726; the Regulations were revoked in so far as they relate to the labelling of containers and packages of medicinal products for administration in certain medicinal tests on animals by S.I. 1996/2194.
F7As amended by S.I. 1994/3144.
7. In the Medicines (Fluted Bottles) Regulations 1978 F8, in regulation 3 (exceptions)—U.K.
(a)after paragraph (e), insert the following paragraph—
“(ee)where medicinal products are investigational medicinal products within the meaning given by the Medicines for Human Use (Clinical Trials) Regulations 2004;”; and
(b)in paragraph (g), omit “clinical trial certificate or”.
Textual Amendments
F8S.I. 1978/40; regulation 3 was amended by S.I. 1994/3142 and 3144.
8. In Schedule 1 to the Medicines (Fixing of Fees Relating to Medicinal Products for Human Use) Order 1989 F9, after paragraph 9A F10 insert the following paragraph—U.K.
“9B. Functions of the licensing authority which are functions of theirs by virtue of the Medicines for Human Use (Clinical Trials) Regulations 2004 and the functions of any person appointed under Schedule 5 or 8 to those Regulations.”.
9. In the Medicines Act 1968 (Application to Radiopharmaceutical-Associated Products) Regulations 1992 F11, in the Schedule—U.K.
(a)in the entry relating to section 44 of the Act, for “ “, or of a clinical trial certificate or animal test certificate,”” substitute “ , or of an animal test certificate, ”;
(b)in the entry relating to section 45 of the Act, omit “section 31,”, in both places those words appear;
(c)in the entry relating to section 46 of the Act, for “ “or of a clinical trial certificate or animal test certificate”” substitute “ or of an animal test certificate ”; and
(d)in the entry relating to section 47 of the Act—
(i)for “ “any clinical trial certificate or animal test certificate”” substitute “ any animal test certificate ”, and
(ii)for “ “, or any clinical trial certificate or animal test certificate,”” substitute “ , or any animal test certificate, ”.
Textual Amendments
10. In the Medicines (Homoeopathic Medicinal Products for Human Use) Regulations 1994 F12, in Schedule 4 (application of the provisions of the Act)—U.K.
(a)in the entry relating to section 23 of the Act, omit “clinical trials and”;
(b)in the entry relating to section 44 of the Act, for “a clinical trial certificate or animal test certificate”, in both places those words appear, substitute “ an animal test certificate ”;
(c)in the entry relating to section 45 of the Act—
(i)omit “section 31,”, and
(ii)for “ “or of a clinical trial certificate or animal test certificate”” substitute “ or of an animal test certificate ”; and
(d)in the entry relating to section 46 of the Act, for “ “or of a clinical trial certificate or animal test certificate”” substitute “ or of an animal test certificate ”.
Textual Amendments
11. In the Dangerous Substances and Preparations (Safety) (Consolidation) Regulations 1994 F13, in regulation 1 (citation, commencement and interpretation), in paragraph (2), in the definition of “medicinal product”—U.K.
(a)for sub-paragraph (ii), substitute the following sub-paragraph—
“(ii)which is an “investigational medicinal product” within the meaning of regulation 2(1) of the Medicines for Human Use (Clinical Trials) Regulations 2003, or”; and
(b)omit sub-paragraph (iii).
Textual Amendments
F13S.I. 1994/2844; regulation 1(2) was substituted by S.I. 1996/2635.
12. In the Medicines for Human Use (Marketing Authorisations Etc.) Regulations 1994 F14—U.K.
(a)in regulation 1—
(i)in paragraph (2), after the definition of “the Act” insert the following definition—
““the Clinical Trials Directive” means Directive 2001/20/EC of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use;”,
(ii)in paragraph (5), omit “and except in the case of “clinical trial,””; and
(b)in Schedule 1, in paragraph 2, for sub-paragraph (e) F15 substitute the following sub-paragraph—
“(e)the relevant medicinal product—
(i)is manufactured, assembled or imported by the holder of an authorization referred to in Article 40 of the 2001 Directive which relates specifically to the manufacture, assembly or import of relevant medicinal products to which paragraph 1 applies; or
(ii)has been manufactured, assembled or imported as an investigational medicinal product by the holder of an authorization referred to in Article 13 of the Clinical Trials Directive”; and.
13. In the Prescription Only Medicines (Human Use) Order 1997 F16—U.K.
(a)in article 1 (citation, commencement and interpretation), in paragraph (2), for the definition of “clinical trial exemption” substitute the following definition—
““clinical trial” has the meaning given by regulation 2(1) of the Medicines for Human Use (Clinical Trials) Regulations 2003;”; and
(b)in article 3B (prescribing and administration by supplementary prescribers), in paragraph (3), in sub-paragraph (b), in head (ii), for the words from “and—” to the end substitute “ which has been authorised, or is to be treated as having been authorised, by the licensing authority in accordance with the Medicines for Human Use (Clinical Trials) Regulations 2003 ”.
Textual Amendments
F16S.I. 1997/1830; the relevant amending instrument is S.I. 2003/696.
14. In the Ionising Radiation (Medical Exposure) Regulations 2000 F17, in regulation 2 (interpretation), in paragraph (1), after the definition of “ionising radiation”, insert the following definition—U.K.
““Local Research Ethics Committee” means—
an ethics committee established or recognised in accordance with Part 2 of the Medicines for Human Use (Clinical Trials) Regulations 2004,
the Ethics Committee constituted by regulations made by the Scottish Ministers under section 51(6) of the Adults with Incapacity (Scotland) Act 2000, or
any other committee established to advise on the ethics of research investigations in human beings, and recognised for that purpose by or on behalf of the Secretary of State, the National Assembly for Wales or Scottish Ministers;”.
Textual Amendments
15. In the Private and Voluntary Health Care (England) Regulations 2001 F18, in regulation 24 (research), for paragraph (2) substitute the following paragraph—U.K.
“(2) For the purposes of paragraph (1)(a), “appropriate Research Ethics Committee” means—
(a)an ethics committee established or recognised in accordance with Part 2 of the Medicines for Human Use (Clinical Trials) Regulations 2004; or
(b)any other committee established to advise on the ethics of research investigations in human beings, and recognised for that purpose by or on behalf of the Secretary of State;”.
Textual Amendments
16. In the Misuse of Drugs Regulations 2001 F19, in regulation 18 (marking of bottles and other containers), for paragraph (3) substitute the following paragraph—U.K.
“(3) In this regulation—
“clinical trial” has the same meaning as in the Medicines for Human Use (Clinical Trials) Regulations 2003;
“medicinal test on animals” has the same meaning as in the Medicines Act 1968.”.
Textual Amendments
17. In the Health Service (Control of Patient Information) Regulations 2002 F20, in regulation 1 (citation, commencement, interpretation and extent), in paragraph (2), for the definition of “research ethics committee” substitute the following definition—U.K.
““research ethics committee” means—
an ethics committee established or recognised in accordance with Part 2 of the Medicines for Human Use (Clinical Trials) Regulations 2004, or
any other committee established to advise on the ethics of research investigations in human beings, and recognised for that purpose by or on behalf of the Secretary of State or the National Assembly for Wales;”.
Textual Amendments
18. In the National Health Service (Functions of Strategic Health Authorities and Primary Care Trusts and Administration Arrangements) (England) Regulations 2002 F21, in regulation 2 (interpretation), in paragraph (1), for the definition of “research ethics committee” substitute the following definition—U.K.
““research ethics committee” means—
an ethics committee established or recognised in accordance with Part 2 of the Medicines for Human Use (Clinical Trials) Regulations 2004, or
any other committee established to advise on the ethics of research investigations on human beings and recognised for that purpose by or on behalf of the Secretary of State;”.
Textual Amendments
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: